SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021

New York, New York – (Newsfile Corp. – December 3, 2021) – The following statement is issued by Levi & Korsinsky, LLP:

To: Any person or entity who purchased or otherwise acquired BioMarin Pharmaceutical Inc. (“BioMarin”) (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021. You are hereby notified that a class action lawsuit has been filed in the United States District Court for the Northern District of California. For more information, please visit: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21874&wire=5 or contact Joseph E. Levi, Esq. either by email at jlevi@levikorsinsky.com or by phone at (212) 363-7500. There are no costs or obligations for you.

BioMarin Pharmaceutical Inc. NEWS – BMRN NEWS

CASE DETAILS: According to the complaint filed: (i) BMN 307, an adeno-associated virus vector-mediated gene transfer of human phenylalanine hydroxylase, was less secure than BioMarin would have investors believe; (ii) the safety profile of BMN 307 made it likely that the Food and Drug Administration would clinically suspend the Phase 1/2 study of Phearless; (iii) accordingly, the Company had overstated the clinical and commercial prospects of BMN 307; and (iv) as a result, the Company’s public statements at all relevant times have been materially false and misleading.

WHAT THIS MEANS FOR SHAREHOLDERS: If you have suffered a loss at BioMarin, you can apply until December 22, 2021 for the court to appoint you as the lead plaintiff. Your ability to partake in a recovery does not require you to be the lead plaintiff.

COST TO YOU: If you purchased BioMarin securities between January 13, 2020 and September 3, 2021, you may be entitled to compensation with no out-of-pocket expenses or fees.

PROTECT YOUR FINANCIAL INTERESTS: Fill out this short submission form https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21874&wire=5 or call 212- 363-7500 to discuss the case with Joseph E. Levi, Esq.

The story goes on

WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven record of winning hundreds of millions of dollars worth of cases for shareholders over a period of 20 years. We represent and fight for shareholders who have been disadvantaged by companies.

Levi & Korsinsky is a nationally recognized law firm with offices in New York, California, Connecticut and Washington, DC. The firm’s founding partners, Joseph Levi and Eduard Korsinsky, have represented shareholders and institutional clients for nearly 20 years and have had remarkable results for clients in the US and internationally. The company, with more than 80 employees, is committed to promoting, nurturing and maintaining a culture of diversity, equality and inclusion for employees and those we represent. Our attorneys have extensive experience representing investors in securities disputes with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked one of the leading securities litigation firms in the United States in the SCAS Top 50 Report by Institutional Shareholder Services (“ISS”) for 7 consecutive years. The SCAS Top 50 Report identifies the leading securities law firms in the country, and year on year ISS has recognized Levi & Korsinsky as the leading class of securities law firm.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106456

Comments are closed.